Contact Us

You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Contact Us

If you have any questions about ZERVIATE®, call us at 1-833-442-7769 (1-833-4HARROW). You can also fill out the form below and click submit.

First Name*

Last Name*

Email Address*

Phone Number*

State*

Role*

Facility*

Specialty*

*Required field.

I authorize Harrow, Inc., to send me emails regarding ZERVIATE® and other informational materials. I understand that I may revoke this authorization and choose not to receive information from Harrow by clicking the “unsubscribe” link provided in emails I receive from Harrow. I have read and understand Harrow’s Privacy Notice.

INDICATIONS AND USAGE

ZERVIATE® (cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis.

DOSAGE AND ADMINISTRATION

Instill one drop of ZERVIATE in each affected eye twice daily (approximately 8 hours apart).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Contamination of Tip and Solution: As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.

Contact Lens Wear: Patients should be advised not to wear a contact lens if their eye is red. ZERVIATE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIATE. The preservative in ZERVIATE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE.

ADVERSE REACTIONS

The most commonly reported adverse reactions occurred in approximately 1%–7% of patients treated with either ZERVIATE or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

Please see the full Prescribing Information.

References: 1. ZERVIATE [package insert]. Fort Worth, TX: Eyevance Pharmaceuticals LLC; 2020. 2. Meier EJ, Torkildsen GL, Gomes PJ, et al. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. Clin Ophthalmol. 2018;12:2617-2628. 3. US Department of Health and Human Services, Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. (Orange Book). 40th ed. Washington, DC: US Department of Health and Human Services, Food and Drug Administration; 2020. 4. Malhotra RP, Meier E, Torkildsen G, et al. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. Clin Ophthalmol. 2019;13:403-413.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Please see the full Prescribing Information.